跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 12,279 条关于
“HER2-altered NSCLC”
全部
12,279
临床试验
8,893
药物
355
机构
21
资讯
3,010
去年
Bayer's BAY 2927088 Advances to Phase 3 Trial for HER2-Mutated NSCLC
去年
Nuvalent Appoints Grant Bogle to Board of Directors, Strengthening Oncology Focus
去年
Nuvalent Fast-Tracks First Approval for Zidesamtinib in ROS1-Positive NSCLC by 2026
3天前
Zidesamtinib Delivers 94% Response Rate in TKI-Naive ROS1-Positive NSCLC, Supporting First-Line Filing
去年
Nuvalent Advances Toward First NDA Submission with Pivotal Data Expected for ROS1 and ALK Inhibitors in 2025
去年
HER2-Targeted Therapies Evolve in NSCLC Treatment Landscape
去年
Trastuzumab Deruxtecan Shows Promise in HER2-Overexpressing NSCLC
2年前
Zongertinib Shows Promise in HER2-Mutated NSCLC, Phase 3 Trial Underway
去年
Tepotinib Shows High Frequency of Adverse Events but Manageable Safety Profile in MET Exon 14-Altered NSCLC
去年
Zongertinib Shows Promise in HER2-Mutated NSCLC, Gains Breakthrough Therapy Designation
第 1 页,共 301 页
上一页
下一页